These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1121 related articles for article (PubMed ID: 2494733)

  • 61. Selective uptake of para-boronophenylalanine increases in amelanotic melanoma cells transfected by the tyrosinase gene.
    Hiratsuka J; Kondoh H; Tsuboi T; Yoshino K; Imajo Y; Mishima Y
    Melanoma Res; 2000 Jun; 10(3):297-302. PubMed ID: 10890385
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer.
    Ichikawa H; Taniguchi E; Fujimoto T; Fukumori Y
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S111-4. PubMed ID: 19376721
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of dose measuring system for thermal neutron capture therapy.
    Matsumoto T; Aizawa O; Nozaki T; Sato T
    Strahlenther Onkol; 1989; 165(2-3):112-5. PubMed ID: 2494711
    [No Abstract]   [Full Text] [Related]  

  • 64. Enhanced survival in a rat glioma model following BNCT.
    Clendenon NR; Barth RF; Goodman JH; Staubus AE; Gordon WA; Moeschberger ML; Alam F; Soloway AH; Fairchild RG; Slatkin DN
    Strahlenther Onkol; 1989; 165(2-3):222-5. PubMed ID: 2494736
    [No Abstract]   [Full Text] [Related]  

  • 65. Human melanoma treated by boron neutron capture therapy: comparison of the clinical response with the predicted response.
    Hiratsuka J; Fukuda H; Kobayashi T; Kanda K; Honda C; Ichihashi M; Mishima Y
    Radiat Med; 1996; 14(5):257-63. PubMed ID: 8988505
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Three cases of terminal stage malignant gliomas in which the diffusely disseminated intraventricular tumors became the target of boron neutron capture therapy.
    Montagno Ede A; Moreira Filho L; Hatanaka H
    Strahlenther Onkol; 1989; 165(2-3):238-40. PubMed ID: 2494740
    [No Abstract]   [Full Text] [Related]  

  • 67. In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy.
    Yong JH; Barth RF; Wyzlic IM; Soloway AH; Rotaru JH
    Anticancer Res; 1995; 15(5B):2033-8. PubMed ID: 8572598
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of L-10B-p-boronophenylalanine-fructose and the boron neutron capture reaction on mouse brain dopaminergic neurons.
    Setiawan Y; Halliday GM; Harding AJ; Moore DE; Allen BJ
    Cancer Res; 1995 Feb; 55(4):874-7. PubMed ID: 7850802
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Boron compounds for neutron capture therapy.
    Alam F; Soloway AH; Bapat BV; Barth RF; Adams DM
    Basic Life Sci; 1989; 50():107-11. PubMed ID: 2751601
    [No Abstract]   [Full Text] [Related]  

  • 70. Radiation field for BNCT experiments.
    Csom G; Zsolnay EM; Fehér S; Virágh E
    Strahlenther Onkol; 1989; 165(2-3):78-81. PubMed ID: 2494749
    [No Abstract]   [Full Text] [Related]  

  • 71. Canine spontaneous brain tumors--a large animal model for BNCT.
    Gavin PR; Kraft SL; Wendling LR; Miller DL
    Strahlenther Onkol; 1989; 165(2-3):225-8. PubMed ID: 2494737
    [No Abstract]   [Full Text] [Related]  

  • 72. A multidisciplinary program leading to a clinical trial of neutron capture therapy at Tufts-New England Medical Center and the Massachusetts Institute of Technology.
    Zamenhof RG; Madoc-Jones H; Harling OK; Bernard JA
    Strahlenther Onkol; 1989; 165(2-3):254-7. PubMed ID: 2538941
    [No Abstract]   [Full Text] [Related]  

  • 73. Thermal neutron capture therapy of malignant melanoma using 10B-monoclonal antibodies: in vitro and in vivo analysis.
    Komura A; Nakagawa T; Ichihashi M; Mishima Y
    Melanoma Res; 1992; 1(5-6):397-403. PubMed ID: 1422196
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Perspectives of the clinical BNCT of malignant gliomas in Czechoslovakia.
    Sourek K; Tovarys F
    Strahlenther Onkol; 1989; 165(2-3):247-9. PubMed ID: 2494741
    [No Abstract]   [Full Text] [Related]  

  • 75. Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy.
    Dagrosa MA; Viaggi M; Rebagliati RJ; Batistoni D; Kahl SB; Juvenal GJ; Pisarev MA
    Mol Pharm; 2005; 2(2):151-6. PubMed ID: 15804189
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel boronated-porphyrin as a radio-sensitizing agent for boron neutron capture therapy of tumours: in vitro and in vivo studies.
    Jori G; Soncin M; Friso E; Vicente MG; Hao E; Miotto G; Colautti P; Moro D; Esposito J; Rosi G; Nava E; Sotti G; Fabris C
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S321-4. PubMed ID: 19376726
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of ionizing radiation and dexamethasone on the blood-brain-barrier and blood-tumor-barrier: implications for boron neutron capture therapy of brain tumors.
    Dorn RV; Spickard JH; Griebenow ML
    Strahlenther Onkol; 1989; 165(2-3):219-21. PubMed ID: 2494735
    [No Abstract]   [Full Text] [Related]  

  • 78. Use of nude mice in experimental neutron capture therapy with 10B-BPA.
    Tamaoki N; Ueda M; Tamauchi S; Yamamoto K; Mishima Y
    Pigment Cell Res; 1989; 2(4):343-4. PubMed ID: 2798327
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumor-seeking compounds for boron neutron capture therapy: synthesis and biodistribution.
    Gabel D
    Basic Life Sci; 1989; 50():233-41. PubMed ID: 2751613
    [No Abstract]   [Full Text] [Related]  

  • 80. Boron chemistry and target cell affinity.
    Soloway AH; Alam F; Barth RF; Bapat BV
    Strahlenther Onkol; 1989; 165(2-3):118-20. PubMed ID: 2494713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.